PMID- 35127585
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220208
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Electronic)
IS  - 2296-2360 (Linking)
VI  - 9
DP  - 2021
TI  - HLA-Haploidentical Family Donors: The New Promise for Childhood Acute 
      Lymphoblastic Leukaemia?
PG  - 758680
LID - 10.3389/fped.2021.758680 [doi]
LID - 758680
AB  - Allogeneic haematopoietic stem cell transplantation (HSCT) is indicated in 
      children with high-risk, relapsed or refractory acute lymphoblastic leukaemia 
      (ALL). HLA-matched grafts from cord blood and stem cell repositories have allowed 
      patients without suitable sibling donors to undergo HSCT. However, challenges in 
      procuring matched unrelated donor (MUD) grafts due to high cost, ethnic disparity 
      and time constraints have led to the exponential rise in the use of stem cells 
      from human leukocyte antigen (HLA)-haploidentical family donors. Whilst 
      HLA-haploidentical HSCT (hHSCT) performed in adult patients with acute leukaemia 
      has produced outcomes similar to MUD transplants, experience in children is 
      limited. Over the last 5 years, more data have emerged on hHSCT in the childhood 
      ALL setting, allowing comparisons with matched donor transplants. The feasibility 
      of hHSCT using adult family donors in childhood ALL may also address the ethical 
      issues related to selection of minor siblings in matched sibling donor 
      transplants. Here, we review hHSCT in paediatric recipients with ALL and 
      highlight the emergence of hHSCT as a promising therapeutic option for patients 
      lacking a suitable matched donor. Recent issues related to conditioning regimens, 
      donor selection and graft-vs.-host disease prophylaxis are discussed. We also 
      identify areas for future research to address transplant-related complications 
      and improve post-transplant disease-free survival.
CI  - Copyright (c) 2022 Ab Rahman, Matic, Yordanova and Ariffin.
FAU - Ab Rahman, Syaza
AU  - Ab Rahman S
AD  - Paediatric Haematology-Oncology and Bone Marrow Transplantation Unit, University 
      of Malaya Medical Centre, Kuala Lumpur, Malaysia.
FAU - Matic, Toni
AU  - Matic T
AD  - Department of Paediatrics, University Hospital Centre, Zagreb, Croatia.
FAU - Yordanova, Maya
AU  - Yordanova M
AD  - Children's Oncohematology Unit, Queen Johanna University Hospital, Sofia, 
      Bulgaria.
FAU - Ariffin, Hany
AU  - Ariffin H
AD  - Paediatric Haematology-Oncology and Bone Marrow Transplantation Unit, University 
      of Malaya Medical Centre, Kuala Lumpur, Malaysia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220121
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC8814573
OTO - NOTNLM
OT  - acute lymphoblastic leukaemia (ALL)
OT  - haematopoietic stem cell transplantation
OT  - haploidentical
OT  - human leukocyte antigen
OT  - paediatric
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. The handling editor declared a shared consortium with 
      several of the authors HA and TM at time of review.
EDAT- 2022/02/08 06:00
MHDA- 2022/02/08 06:01
PMCR- 2022/01/21
CRDT- 2022/02/07 05:34
PHST- 2021/08/14 00:00 [received]
PHST- 2021/09/30 00:00 [accepted]
PHST- 2022/02/07 05:34 [entrez]
PHST- 2022/02/08 06:00 [pubmed]
PHST- 2022/02/08 06:01 [medline]
PHST- 2022/01/21 00:00 [pmc-release]
AID - 10.3389/fped.2021.758680 [doi]
PST - epublish
SO  - Front Pediatr. 2022 Jan 21;9:758680. doi: 10.3389/fped.2021.758680. eCollection 
      2021.